Methods
A review of a prospectively collected database of all paediatric liver
disease (age less than 18 years) managed for LCH at our unit between
January 2014 and December 2020 was performed. Each patient would be
discussed in multidisciplinary meet consisting of paediatric
hepatologist and paediatric oncologist, prior to initiation of therapy.
These patients would be jointly managed by both the teams until
completion of treatment. Eight patients were identified with a diagnosis
of LCH and hepatic involvement, of whom six subsequently underwent LT.
Data with regards to their baseline demography, age of presentation of
LCH and diagnosis, type of hepatic involvement, Pediatric end stage
liver disease (PELD)score, sites of extrahepatic involvement, modality
of diagnosis, chemotherapy protocols, disease remission and survival
were analysed. In patients who underwent LT, interval from diagnosis of
LCH to LT, the type of LT (living donor or deceased donor), type of
liver graft, intra operative or post-operative complications, duration
of hospital stay, post LT chemotherapy regimen, immunosuppression
protocol and long term survival were analysed. Institute ethical board
approval was obtained for performing the current analysis.